Top Amneal Executives Quietly Cash In on Major Stock Sale
I'm LongbridgeAI, I can summarize articles.Amneal Pharmaceuticals executives Jason B. Daly and Nikita Shah sold significant stock blocks on August 13, 2026, generating over $6 million combined. This insider selling coincides with positive developments, including the Kashiv BioSciences acquisition, Q2 earnings beats, raised guidance, and term loan repricing. Despite these fundamentals driving a 'Buy' technical signal and YTD gains of 40%, TipRanks AI analyst Spark rates AMRX as Neutral due to high leverage, weak free cash flow, and rich valuation.
New insider activity at Amneal Pharmaceuticals ( (AMRX) ) has taken place on August 13, 2026.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Amneal Pharmaceuticals has seen notable insider selling activity, as two top executives unloaded substantial blocks of company stock. EVP and Chief Legal Officer Jason B. Daly sold 216,613 shares of Amneal Pharmaceuticals, generating proceeds of $3,771,050. In a separate transaction, EVP Nikita Shah sold 146,403 shares, with the sale totaling $2,563,516. These sizable sales by senior leadership highlight significant recent movement in Amneal’s insider ownership positions.
Recent Updates on AMRX stock
In the last day, Amneal Pharmaceuticals’ stock has been driven by news of strategic expansion and strong fundamentals. The completion of its Kashiv BioSciences acquisition builds a fully integrated biosimilars platform, supporting expectations for long-term growth as biologic drugs lose exclusivity, which underpins more optimistic analyst outlooks.
At the same time, Amneal’s Q2 earnings beat and raised guidance, alongside near-term biosimilar and generic launches, are cited as key reasons for recent price target revisions. Its term loan repricing to cut interest costs and improve financial flexibility further supports sentiment, though analysts still flag high leverage and rich valuation as important offsetting risks.
Spark’s Take on AMRX Stock
According to Spark, TipRanks’ AI Analyst, AMRX is a Neutral.
AMRX scores as a moderate-risk, improving story: operating performance and the latest guidance raise are clear positives, supported by a constructive price trend. The score is held back primarily by the highly leveraged balance sheet and recently weaker free cash flow, while valuation (P/E ~35.9 and no dividend) provides limited margin of safety.
To see Spark’s full report on AMRX stock,
click here.
More about Amneal Pharmaceuticals
YTD Price Performance: 40.16%
Average Trading Volume: 1,999,580
Technical Sentiment Signal: Buy
Current Market Cap: $5.46B